Pre-exposure Prophylaxis Discontinuation During the COVID-19 Pandemic Among Men Who Have Sex With Men in a Multisite Clinical Cohort in the United States
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved..
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic continues to put strain on health systems in the United States, leading to significant shifts in the delivery of routine clinical services, including those offering HIV pre-exposure prophylaxis (PrEP). We aimed to assess whether individuals discontinued PrEP use at higher rates during the COVID-19 pandemic and the extent to which disruptions to usual clinical care were mitigated through telehealth.
METHODS: Using data from an ongoing prospective cohort of men who have sex with men (MSM) newly initiating PrEP in 3 mid-sized cities (n = 195), we calculated the rate of first-time discontinuation of PrEP use in the period before the COVID-19 pandemic and during the COVID-19 pandemic and compared these rates using incidence rate ratios (IRRs). Furthermore, we compared the characteristics of patients who discontinued PrEP use during these periods with those who continued to use PrEP during both periods.
RESULTS: Rates of PrEP discontinuation before the COVID pandemic and during the COVID-19 pandemic were comparable [4.29 vs. 5.20 discontinuations per 100 person-months; IRR: 1.95; 95% confidence interval (CI): 0.83 to 1.77]. Although no significant differences in the PrEP discontinuation rate were observed in the overall population, the rate of PrEP discontinuation increased by almost 3-fold among participants aged 18-24 year old (IRR: 2.78; 95% CI: 1.48 to 5.23) and by 29% among participants covered by public insurance plans at enrollment (IRR: 1.29; 95% CI: 1.03 to 5.09). Those who continued to use PrEP were more likely to have had a follow-up clinical visit by telehealth in the early months of the pandemic (45% vs. 17%).
CONCLUSIONS: In this study, rates of PrEP discontinuation were largely unchanged with the onset of the COVID-19 pandemic. The use of telehealth likely helped retain patients in PrEP care and should continue to be offered in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:91 |
|---|---|
| Enthalten in: |
Journal of acquired immune deficiency syndromes (1999) - 91(2022), 2 vom: 01. Okt., Seite 151-156 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goedel, William C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-HIV Agents |
|---|
| Anmerkungen: |
Date Completed 14.09.2022 Date Revised 02.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/QAI.0000000000003042 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346114403 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346114403 | ||
| 003 | DE-627 | ||
| 005 | 20231226030640.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/QAI.0000000000003042 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1153.xml |
| 035 | |a (DE-627)NLM346114403 | ||
| 035 | |a (NLM)36094480 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goedel, William C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pre-exposure Prophylaxis Discontinuation During the COVID-19 Pandemic Among Men Who Have Sex With Men in a Multisite Clinical Cohort in the United States |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.09.2022 | ||
| 500 | |a Date Revised 02.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic continues to put strain on health systems in the United States, leading to significant shifts in the delivery of routine clinical services, including those offering HIV pre-exposure prophylaxis (PrEP). We aimed to assess whether individuals discontinued PrEP use at higher rates during the COVID-19 pandemic and the extent to which disruptions to usual clinical care were mitigated through telehealth | ||
| 520 | |a METHODS: Using data from an ongoing prospective cohort of men who have sex with men (MSM) newly initiating PrEP in 3 mid-sized cities (n = 195), we calculated the rate of first-time discontinuation of PrEP use in the period before the COVID-19 pandemic and during the COVID-19 pandemic and compared these rates using incidence rate ratios (IRRs). Furthermore, we compared the characteristics of patients who discontinued PrEP use during these periods with those who continued to use PrEP during both periods | ||
| 520 | |a RESULTS: Rates of PrEP discontinuation before the COVID pandemic and during the COVID-19 pandemic were comparable [4.29 vs. 5.20 discontinuations per 100 person-months; IRR: 1.95; 95% confidence interval (CI): 0.83 to 1.77]. Although no significant differences in the PrEP discontinuation rate were observed in the overall population, the rate of PrEP discontinuation increased by almost 3-fold among participants aged 18-24 year old (IRR: 2.78; 95% CI: 1.48 to 5.23) and by 29% among participants covered by public insurance plans at enrollment (IRR: 1.29; 95% CI: 1.03 to 5.09). Those who continued to use PrEP were more likely to have had a follow-up clinical visit by telehealth in the early months of the pandemic (45% vs. 17%) | ||
| 520 | |a CONCLUSIONS: In this study, rates of PrEP discontinuation were largely unchanged with the onset of the COVID-19 pandemic. The use of telehealth likely helped retain patients in PrEP care and should continue to be offered in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 700 | 1 | |a Rogers, Brooke G |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Nunn, Amy S |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Rupa R |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, Brandon D L |e verfasserin |4 aut | |
| 700 | 1 | |a Mena, Leandro A |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Lori M |e verfasserin |4 aut | |
| 700 | 1 | |a Brock, J Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Napoleon, Siena |e verfasserin |4 aut | |
| 700 | 1 | |a Zanowick-Marr, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Curoe, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Underwood, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Catrell J |e verfasserin |4 aut | |
| 700 | 1 | |a Lockwood, Khadijra R |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Philip A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of acquired immune deficiency syndromes (1999) |d 1999 |g 91(2022), 2 vom: 01. Okt., Seite 151-156 |w (DE-627)NLM101679912 |x 1944-7884 |7 nnns |
| 773 | 1 | 8 | |g volume:91 |g year:2022 |g number:2 |g day:01 |g month:10 |g pages:151-156 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/QAI.0000000000003042 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 91 |j 2022 |e 2 |b 01 |c 10 |h 151-156 | ||